NCT03181529View on ClinicalTrials.gov

Effects of Psilocybin in Major Depressive Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 10, 2017

Primary Completion Date

December 2, 2020

Study Completion Date

December 2, 2020

Conditions
Major Depressive Disorder
Interventions
DRUG

Psilocybin

Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT03181529 - Effects of Psilocybin in Major Depressive Disorder | Biotech Hunter | Biotech Hunter